In a bi-center retrospective study of patients with NSCLC treated with PD-1/PD-L1 inhibitors, Riedl et al. (2020) reported that elevated baseline CRP was an independent predictor of poor prognosis, being significantly associated with reduced progression-free survival (PFS) and overall survival (OS), with hazard ratios per doubling of CRP of 1.37 for PFS and 1.42 for OS [27]. The gene discussed is CRP; the disease is non-small cell lung carcinoma.